Advaxis treatment of osteosarcoma designated for orphan status The company's live attenuated bioengineered Listeria monocytogenes immunotherapy was designated for orphan status as an osteosarcoma treatment, according to a post to the FDA's website. Reference Link
Advaxis names Mauro Chief Medical Officer Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.